Please use this identifier to cite or link to this item: https://repositorio.accefyn.org.co/handle/001/1089 Cómo citar
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDomínguez Romero, Yohana-
dc.contributor.authorSanta, Jorge A.-
dc.contributor.authorBohórquez Villamizar, Luisa F.-
dc.contributor.authorDelgado Murcia, Lucy G.-
dc.date.accessioned2021-12-09T20:37:01Z-
dc.date.available2021-12-09T20:37:01Z-
dc.date.issued2018-10-03-
dc.identifier.urihttps://repositorio.accefyn.org.co/handle/001/1089-
dc.description.abstractEl uso terapéutico de insulina exógena de origen animal para el tratamiento de la diabetes mellitus se ha asociado con la inducción de anticuerpos antiinsulínicos, los cuales alterarían la seguridad y la eficacia de esta formulación. Con la introducción de la tecnología del ADN recombinante y la producción de insulinas con secuencias similares a la humana, se redujo, pero no se eliminó, la aparición de dichos anticuerpos. En el marco del análisis de la inmunogenicidad inducida por las proteínas terapéuticas y con el objetivo de evaluar el perfil de inmunidad humoral de tres formulaciones comerciales de insulina exógena humana (insulina regular, insulina Neutral protamine Hagedorn [NPH], e insulina glargina), se estudió la presencia de anticuerpos antiinsulínicos en 29 muestras de suero de pacientes con diabetes tipo 2, y se caracterizó su reactividad cruzada, su perfil según la subclase de IgG y su capacidad para formar complejos inmunitarios. Los pacientes se clasificaron en tres grupos según su tratamiento: a) insulina regular y NPH (n=10), b) insulina NPH (n=9) y c) glargina (n=10). La detección, caracterización y evaluación de las subclases de IgG se hizo mediante ELISA indirecto, y la detección de complejos inmunitarios constituidos por anticuerpos antiinsulínicos e insulina exógena, mediante ELISA de captura. Los resultados permitieron evidenciar que: i) cada formulación de insulina es reconocida de manera diferencial por los anticuerpos antiinsulínicos, lo cual sugiere un mayor potencial inmunogénico de la insulina NPH y uno menor de la insulina glargina; ii) el perfil según la subclase de IgG de los anticuerpos antiinsulínicos en humanos es diferencial para cada formulación, siendo predominante la subclase IgG3 para la insulina NPH en pacientes en tratamiento con insulina regular y NPH; iii) la presencia de anticuerpos antiinsulínicos no se asoció con alteraciones de los parámetros metabólicos analizados, y iv) los complejos inmunitarios constituidos por anticuerpos antiinsulínicos e insulina exógena no se detectaron con la metodología utilizada en los sueros de los pacientes con diabetes tipo 2 estudiados. Los resultados obtenidos permiten concluir que existen diferencias entre el perfil inmunogénico de las insulinas evaluadas, lo cual es importante en el análisis de la inmunogenicidad de dichas formulaciones en cuanto a su seguridad y eficacia.spa
dc.description.abstractThe therapeutic use of exogenous insulin of animal origin for the treatment of diabetes mellitus has been associated with the development of insulin antibodies, which raises concerns regarding the safety and efficacy of this formulation. With the advent of recombinant DNA technology and the generation of insulin with human-like sequences, the production of insulin antibodies has been reduced but not eliminated. As part of the analysis of immunogenicity induced by therapeutic proteins and to evaluate the immunogenic profile of three commercial formulations of human exogenous insulin (regular, neutral protamine Hagedorn (NPH), and glargine) we evaluated the presence of insulin antibodies in 29 serum samples from volunteers with type 2 diabetes, and we characterized their cross-reactivity, IgG subclass profile, and ability to form immune complexes. To this end, volunteers were classified into three groups according to their current insulin therapy: a) Regular and NPH insulin (n=10); b) NPH (n=9), and c) glargine (n=10). For the detection, characterization, and evaluation of the IgG subclasses we used an indirect ELISA test, and for the detection of immune complexes formed by insulin antibodies and exogenous insulin, capture ELISA. Our results evidenced that: i) Each insulin formulation was recognized differentially by the insulin antibodies suggesting a greater immunogenic potential for NPH insulin and a lower one for glargine insulin; ii) the IgG subclasses profile of insulin antibodies in humans was different for each formulation; the IgG3 subclass for NPH insulin was predominant in volunteers treated with regular and NPH insulin; iii) the presence of insulin antibodies was not associated with alterations in the metabolic parameters analyzed, and iv) immune complexes composed of exogenous insulin antibodies were not detected in the sera of diabetic volunteers. The results obtained in this study allowed us to conclude that there are differences between the immunogenic profile of the insulin formulations tested, which has significant value in the analysis of their immunogenicity with regard to their safety and efficacy.eng
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.publisherAcademia Colombiana de Ciencias Exactas, Físicas y Naturalesspa
dc.rightsCreative Commons Attribution-NonCommercial-ShareAlike 4.0 Internationalspa
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/spa
dc.sourceRevista de la Academia Colombiana de Ciencias Exactas, Físicas y Naturalesspa
dc.titleEstudio preliminar de anticuerpos IgG antiinsulínicos y complejos inmunitarios en pacientes colombianos con diabetes tipo 2spa
dc.typeArtículo de revistaspa
dcterms.audienceEstudiantes, Profesores, Comunidad científica colombianaspa
dcterms.referencesAmerican Diabetes Association (ADA). (2014) Standards of Medical Care in Diabetes. Diabetes Care. 37 (Supplement 1): S14-S80.spa
dcterms.referencesAsociación Latinoamericana de Diabetes (ALAD). (2013). Guías ALAD de diagnóstico control y tratamiento de la diabetes mellitus tipo 2. Fecha de consulta: 1 de junio de 2018. Disponible en: https://issuu.com/alad-diabetes/docs/guias_alad_2013spa
dcterms.referencesAndersen, O. O. (1976). Clinical significance of anti-insulin-antibodies. Acta Endocrinologica. 205: 231-40spa
dcterms.referencesBerson, S. A., Yalow, R. S., Bauman, A., Rothschild, M. A., & Newerly, K. (1956). Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. The Journal of Clinical Investigation, 35 (2): 170-190.spa
dcterms.referencesChen, J.-W., Frystyk, J., Lauritzen, T., & Christiansen, J. S. (2005). Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes. European Journal of Endocrinology, 153 (6): 907-913spa
dcterms.referencesComisión de regulación en salud. (2011). Actualización de Plan Obligatorio de Salud. Bogotá. Pag.115spa
dcterms.referencesDevey, M. (1988). Clinical Aspects of IgG Subclasses and Therapeutic Implications. Immunology, 65 (2): 327spa
dcterms.referencesDi Mario, U., Ventriglia, L., Iavicoli, M., Guy, K., & Andreani, D. (1983). The correlation between insulin antibodies and circulating immune complexes in diabetics with and without microangiopathy. Clinical And Experimental Immunology, 52 (3): 575-580spa
dcterms.referencesDib, S. A., Freire, M. B., Miranda, W. L., & Russo, E. M. (1994). Detection of insulin antibodies by radioassay and ELISA: interrelation and correlation with metabolic control in type I diabetes. Brazilian Journal of Medical and Biological Research, 27 (5): 1167-1180spa
dcterms.referencesDomínguez Y. (2014). Inmunodetección de anticuerpos anti-insulina libres en suero Y unidos a la molécula de insulina en pacientes insulino-dependientes. Universidad Nacional de Colombia. Tesis. 46-48spa
dcterms.referencesEyzaguirre, F., & Codner, E. (2006). [Insulin analogues: searching for a physiological replacement]. Revista Medica de Chile, 134 (2): 239-50spa
dcterms.referencesFineberg, S. E., Kawabata, T. T., Finco-Kent, D., Fountaine, R. J., Finch, G. L., & Krasner, A. S. (2007). Immunological responses to exogenous insulin. Endocrine Reviews, 28 (6): 625-652spa
dcterms.referencesFrancis, A. J., Hanning, I., & Alberti, K. G. M. M. (1985). The influence of insulin antibody levels on the plasma profiles and action of subcutaneously injected human and bovine short acting insulins. Diabetologia, 28 (6): 330-334spa
dcterms.referencesHattori, N., & Shimatsu, A. (2013). Treatment with insulin glargine causes anti-insulin antibody production more frequently than other insulin analogs in patients with diabetes mellitus. Endocrine Reviews, 34 (3).spa
dcterms.referencesHeding, L. G., Marshall, M. O., Persson, B., Dahlquist, G., Thalme, B., Lindgren, F. Kaad, P. H. (1984). Immunogenicity of monocomponent human and porcine insulin in newly diagnosed Type 1 (insulin-dependent) diabetic children. Diabetologia, 27: 96-98.spa
dcterms.referencesHuber, R. (1980). Spatial structure of immunoglobulin molecules. Klinische Wochenschrift. 58 (22): 1217-1231spa
dcterms.referencesInternational Diabetes Federation. 2017. IDF Diabetes Atlas 2017. Fecha de consulta: 6 de junio de 2018. Disponible en: http://www.diabetesatlas.orgspa
dcterms.referencesIrvine, W., Di Mario, U., Guy, K., Iavicoli, M., Pozzilli, P., Lumbroso, B., & Andreani, D. (1978). Immune complexes and diabetic microangiopathy. Journal of Clinical & Laboratory Immunology, 1 (3): 187-191spa
dcterms.referencesIshizuka, T., Ogawa, S., Mori, T., Nako, K., Nakamichi, T., Oka, Y., & Ito, S. (2009). Characteristics of the antibodies of two patients who developed daytime hyperglycemia and morning hypoglycemia because of insulin antibodies. Diabetes Research and Clinical Practice, 84 (2): 21e-23e.spa
dcterms.referencesItoh, A., Saisho, Y., Mitsuishi, M., Oikawa, Y., Kawai, T., Tanaka, M. (2011). Insulin glulisine may ameliorate nocturnal hypoglycemia related to insulin antibody - A case report. Diabetes Research and Clinical Practice. 94:e53-e54; discussion: e55spa
dcterms.referencesJefferis, R., & Kumararatne, D. S. (1990). Selective IgG subclass deficiency: quantification and clinical relevance. Clinical and Experimental Immunology, 81 (3): 357-367.spa
dcterms.referencesKoch, M., François-Gérard, C., Sodoyez-Goffauxl, F., & Sodoyez, J. C. (1986). Semi-quantitative assessment of anti-insulin total IgG and IgG sub-classes in insulin-immunized patients using a highly sensitive immunochemical micro-method. Diabetologia, 29 (10): 720-726.spa
dcterms.referencesKoyama, R., Nakanishi, K., Kato, M., Yamashita, S., Kuwahara, H., & Katori, H. (2005). Hypoglycemia and hyperglycemia due to insulin antibodies against therapeutic human insulin: Treatment with double filtration plasmapheresis and prednisolone. American Journal of the Medical Sciences, 329 (5): 259-264spa
dcterms.referencesLahtela, J. T., Knip, M., Paul, R., Antonen, J., & Salmi, J.(1997). Severe antibody-mediated human insulin resistance: Successful treatment with the insulin analog lispro: A case report. Diabetes Care, 20 (1): 71-73.spa
dcterms.referencesNyhan, D. P., Shampaine, E. L., Hirshman, C. A., Hamilton, R. G., Frank, S. M., Baumgartner, W. A., & Adkinson, N. F. (1996). Single doses of intravenous protamine result in the formation of protamine-specific IgE and IgG antibodies. Journal of Allergy and Clinical Immunology, 97 (4): 991-997spa
dcterms.referencesOchoa R. (2012). Técnicas inmunoenzimáticas para ensayos clínicos de vacunas y estudios inmunoepidemiológicos. La habanaI. Finlay Ediciones. Pág. 14spa
dcterms.referencesPieber, T. R., Eugène-Jolchine, I., & Derobert, E. (2000). Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care, 23 (2): 157-162.spa
dcterms.referencesRatanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I.(2014). Immunogenicity of therapeutic proteins: Influence of aggregation. Journal of Immunotoxicology. 11 (2): 99-109.spa
dcterms.referencesReeves, W. G., & Kelly, U. (1982). Insulin antibodies induced by bovine insulin therapy. Clinical and Experimental Immunology, 50 (1): 163-170spa
dcterms.referencesSchernthaner, G., Borkenstein, M., Fink, M., Mayr, W. R., Menzel, J., & Schober, E. (1983). Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals. Diabetes Care, 6 (Suppl. 1): 43-48spa
dcterms.referencesSegal, T., Webb, E. A., Viner, R., Pusey, C., Wild, G., & Allgrove, J. (2008). Severe insulin resistance secondary to insulin antibodies: Successful treatment with the immuno-suppressant MMF. Pediatric Diabetes, 9 (3PART1): 250-254.spa
dcterms.referencesSodoyez-Goffaux, F., Koch, M., Dozio, N., Brandenburg, D., & Sodoyez, J. C. (1988). Advantages and pitfalls of radioimmune and enzyme linked immunosorbent assays of insulin antibodies. Diabetologia, 31 (9): 694-702spa
dcterms.referencesSoto A, Deshazo RD, Morgan JE, Mather P, Ibrahim G, Frentz JM, Lauritano AA. (1991). Total IgG and IgG subclass specific antibody responses to insulin in diabetic patients. Annals of Allergy, 67 (5): 499-503spa
dcterms.referencesThalange, N., Bereket, A., Jensen, L. B., Hiort, L. C., & Peterkova, V. (2016). Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2--16 Years. Diabetes Therapy, 7 (4): 713-724spa
dcterms.referencesUrbaniak SJ, & MA, G. (1980). ADCC (K-cell) lysis of human erythrocytes sensitized with rhesus alloantibodies. III. Comparison of IgG anti-D agglutinating and lytic (ADCC) activity and the role of IgG subclasses. British Journal of Haematology, 46 (3): 447-53.spa
dcterms.referencesVajo, Z., Fawcett, J., & Duckworth, W. C. (2001). Recombinant DNA technology in the treatment of diabetes: Insulin analogs. Endocrine Reviews. 22: 706-717spa
dcterms.referencesValla, V. (2010). Therapeutics of Diabetes Mellitus: Focus on Insulin Analogues and Insulin Pumps. Experimental Diabetes Research, 2010: 1-14.spa
dcterms.referencesWeiss, M. E., Nyhan, D. P., Peng, Z. K., Horrow, J. C., Lowenstein, E., & Hirshman, C. A. (1989). Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. Anesthesia and Analgesia, 3 (4): 3-5spa
dcterms.referencesYanai, H., Adachi, H., & Hamasaki, H. (2011). Diabetic ketosis caused by the insulin analog aspart-induced anti-insulin antibody: Successful treatmentwith the newest insulin analog glulisine. Diabetes Care. 34: 108-e108.spa
dcterms.referencesZhao, T. Y., Li, F., & Xiong, Z. Y. (2010). Frequent reoccur-rence of hypoglycemia in a type 2 diabetic patient with insulin antibodies. Molecular Diagnosis and Therapy, 14(4): 237-241.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dc.rights.creativecommonsAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)spa
dc.identifier.doihttps://doi.org/10.18257/raccefyn.558-
dc.subject.proposalAnticuerpos insulinosspa
dc.subject.proposalInsulines antibodieseng
dc.subject.proposalInsulina exógenaspa
dc.subject.proposalExogenous insulineng
dc.subject.proposalComplejo inmunespa
dc.subject.proposalImmune complexeseng
dc.subject.proposalDiabetesspa
dc.subject.proposalDiabeteseng
dc.subject.proposalELISAspa
dc.subject.proposalELISAeng
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.relation.ispartofjournalRevista de la Academia Colombiana de Ciencias Exactas, Físicas y Naturalesspa
dc.relation.citationvolume42spa
dc.relation.citationstartpage166spa
dc.relation.citationendpage179spa
dc.publisher.placeBogotá, Colombiaspa
dc.contributor.corporatenameAcademia Colombiana de Ciencias Exactas, Físicas y Naturalesspa
dc.coverage.countryColombia-
dc.relation.citationissue164spa
dc.type.contentDataPaperspa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
Appears in Collections:BA. Revista de la Academia Colombiana de Ciencias Exactas Físicas y Naturales

Files in This Item:
File Description SizeFormat 
1. Estudio preliminar de anticuerpos IgG antiinsulínicos y complejos inmunitarios.pdfCiencias Biomédicas2.99 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons